Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Citalopram + choline refers to the combination of two agents: **citalopram**, a selective serotonin reuptake inhibitor (SSRI) antidepressant, and **choline**, an essential nutrient (precursor to acetylcholine), or more specifically citicoline (CDP-choline), in published combination research. Citalopram functions as an SSRI, enhancing serotonergic neurotransmission by inhibiting the reuptake of serotonin in the central nervous system, thus alleviating depressive symptoms[2][4]. Choline (in the form of citicoline) acts as a neuroprotective agent and can elevate acetylcholine levels in the brain, which may support cognitive function and neural health. Studies have investigated this combination to address depression, showing that adjuvant administration of choline (citicoline) with citalopram improved antidepressant effects compared to citalopram alone, likely through synergistic impact on neurotransmitter systems[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on citalopram + choline.